Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:GMTX NASDAQ:NAMS NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$21.11-6.3%$23.19$12.21▼$40.70$590.97M-0.19742,085 shs381,879 shsGMTXGemini Therapeutics$61.59+0.3%$58.05$1.16▼$14.10$2.67B-0.12189,291 shs325,465 shsNAMSNewAmsterdam Pharma$25.65+3.1%$22.67$14.06▼$27.29$2.89B-0.01869,300 shs470,598 shsVCELVericel$33.69+0.4%$37.94$33.09▼$63.00$1.70B1.33506,719 shs866,788 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+9.32%+10.44%-7.02%+6.58%-37.56%GMTXGemini Therapeutics+2.94%+2.70%+4.12%+29.75%+20.82%NAMSNewAmsterdam Pharma+1.02%+1.68%+14.87%+27.52%+56.38%VCELVericel-3.03%-6.52%-10.72%-22.70%-31.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$21.11-6.3%$23.19$12.21▼$40.70$590.97M-0.19742,085 shs381,879 shsGMTXGemini Therapeutics$61.59+0.3%$58.05$1.16▼$14.10$2.67B-0.12189,291 shs325,465 shsNAMSNewAmsterdam Pharma$25.65+3.1%$22.67$14.06▼$27.29$2.89B-0.01869,300 shs470,598 shsVCELVericel$33.69+0.4%$37.94$33.09▼$63.00$1.70B1.33506,719 shs866,788 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+9.32%+10.44%-7.02%+6.58%-37.56%GMTXGemini Therapeutics+2.94%+2.70%+4.12%+29.75%+20.82%NAMSNewAmsterdam Pharma+1.02%+1.68%+14.87%+27.52%+56.38%VCELVericel-3.03%-6.52%-10.72%-22.70%-31.59%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M6.47N/AN/A($1.60) per share-13.19GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ANAMSNewAmsterdam Pharma$45.56M63.40N/AN/A$6.91 per share3.71VCELVericel$237.22M7.17$0.29 per share116.36$6.08 per share5.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ANAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)VCELVericel$10.36M$0.12280.7576.56N/A2.85%2.47%1.69%11/6/2025 (Estimated)Latest ANAB, GMTX, NAMS, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 million8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.228.22GMTXGemini TherapeuticsN/A71.4971.49NAMSNewAmsterdam PharmaN/A21.0821.08VCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AGMTXGemini Therapeutics75.42%NAMSNewAmsterdam Pharma89.89%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%GMTXGemini Therapeutics12.90%NAMSNewAmsterdam Pharma20.84%VCELVericel7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10028.00 million18.62 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableVCELVericel30050.46 million46.83 millionOptionableANAB, GMTX, NAMS, and VCEL HeadlinesRecent News About These CompaniesOMERS ADMINISTRATION Corp Invests $723,000 in Vericel Corporation $VCELSeptember 3 at 4:51 AM | marketbeat.com9,769 Shares in Vericel Corporation $VCEL Bought by Jump Financial LLCSeptember 3 at 4:19 AM | marketbeat.comVericel Corporation $VCEL Stock Position Decreased by Raymond James Financial Inc.August 31, 2025 | marketbeat.comNext Century Growth Investors LLC Boosts Stock Position in Vericel Corporation $VCELAugust 30, 2025 | marketbeat.comChamplain Investment Partners LLC Lowers Stock Position in Vericel Corporation $VCELAugust 30, 2025 | marketbeat.comVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025August 28, 2025 | markets.businessinsider.comVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025August 28, 2025 | globenewswire.comNuveen LLC Purchases New Position in Vericel Corporation $VCELAugust 28, 2025 | marketbeat.comWellington Management Group LLP Acquires 74,723 Shares of Vericel Corporation $VCELAugust 25, 2025 | marketbeat.comRussell Investments Group Ltd. Buys 31,635 Shares of Vericel Corporation $VCELAugust 25, 2025 | marketbeat.comAnalysts Set Vericel Corporation (NASDAQ:VCEL) PT at $60.33August 24, 2025 | americanbankingnews.comVanguard Group Inc. Purchases 7,978 Shares of Vericel Corporation $VCELAugust 23, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Buy" by BrokeragesAugust 23, 2025 | marketbeat.comBNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 98,005 Shares of Vericel Corporation $VCELAugust 20, 2025 | marketbeat.comLeerink Partners Raises the PT Vericel (VCEL), Maintains a Buy RatingAugust 20, 2025 | msn.com11 Best Small-Cap Growth Stocks to Buy Right NowAugust 19, 2025 | insidermonkey.comVericel Corporation (NASDAQ:VCEL) Shares Purchased by Lord Abbett & CO. LLCAugust 19, 2025 | marketbeat.comPublic Sector Pension Investment Board Grows Holdings in Vericel Corporation (NASDAQ:VCEL)August 18, 2025 | marketbeat.comInvesco Ltd. Acquires 35,345 Shares of Vericel Corporation (NASDAQ:VCEL)August 18, 2025 | marketbeat.comLPL Financial LLC Has $2.92 Million Holdings in Vericel Corporation (NASDAQ:VCEL)August 18, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Stock Position Reduced by Neuberger Berman Group LLCAugust 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANAB, GMTX, NAMS, and VCEL Company DescriptionsAnaptysBio NASDAQ:ANAB$21.11 -1.42 (-6.32%) Closing price 03:59 PM EasternExtended Trading$21.08 -0.02 (-0.10%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Gemini Therapeutics NASDAQ:GMTX$61.59 +0.19 (+0.31%) As of 09/3/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.NewAmsterdam Pharma NASDAQ:NAMS$25.65 +0.77 (+3.08%) Closing price 03:59 PM EasternExtended Trading$25.62 -0.02 (-0.09%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Vericel NASDAQ:VCEL$33.69 +0.14 (+0.41%) Closing price 03:59 PM EasternExtended Trading$33.67 -0.02 (-0.05%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Ambarella's Earnings Prove Its Edge AI Strategy Is a Winner Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
